小粒径载药微球经导管动脉化疗栓塞术治疗不可切除肝内胆管癌患者的疗效和安全性分析

肝癌电子杂志 ›› 2025, Vol. 12 ›› Issue (4): 8-13.

小粒径载药微球经导管动脉化疗栓塞术治疗不可切除肝内胆管癌患者的疗效和安全性分析

宣志明¹, 姚雪松^2,*, 宋鹏¹, 李书沛¹, 来凤勇¹, 冯烨霞¹

1.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院介入治疗科,广东深圳 518116;
2.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院介入治疗科,北京 100021

收稿日期:2024-09-12 出版日期:2025-12-30 发布日期:2026-01-16
通讯作者: ^* 姚雪松,E-mail：yaoxuesong2005@hotmail.com
基金资助:
深圳市高水平医院建设专项经费（深府办函[2019]284号）

Efficacy and safety analysis in the treatment of unresectable intrahepatic cholangiocarcinoma by transcatheter arterial chemoembolization with small diameter drug-eluting beads

Xuan Zhiming¹, Yao Xuesong^2,*, Song Peng¹, Li Shupei¹, Lai Fengyong¹, Feng Yexia¹

1. Department of Interventional Therapy, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangzhou, China;
2. Department of Interventional Therapy, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received:2024-09-12 Online:2025-12-30 Published:2026-01-16
Contact: ^* Yao Xuesong, E-mail: yaoxuesong2005@hotmail.com

摘要/Abstract

摘要： 目的：分析小粒径载药微球经导管动脉化疗栓塞术（drug-eluting beads transcatheter arterial chemoembolization, DEB-TACE）治疗不可切除肝内胆管癌（intrahepatic cholangiocarcinoma, ICC）患者的疗效及安全性。
方法：回顾性分析2018年3月至2023年12月在中国医学科学院北京协和医学院肿瘤医院深圳医院接受小粒径DEB-TACE的20例不可切除ICC患者的临床资料,评估肿瘤反应、无疾病进展生存期（progression-free survival, PFS)、总生存期及不良事件发生率。
结果：DEB-TACE术后3个月,20例不可切除ICC患者客观缓解率（objective response rate, ORR）和疾病控制率（disease control rate, DCR）分别为60.0%和95.0%,术后6个月分别为30.0%和75.0%,术后9个月分别为10.0%和45.0%。中位总生存期和中位PFS分别为16.4个月和8.3个月。20例不可切除ICC患者DEB-TACE术后常见不良反应有腹痛、胆红素水平升高、恶心/呕吐、转氨酶水平升高等,均为1级或2级,无3级以上不良反应发生。
结论：对于不可切除的ICC患者,小粒径DEB-TACE是一种安全、有效的局部治疗方式。

关键词: 载药微球经导管动脉化疗栓塞术, 小粒径载药微球, 肝内胆管癌

Abstract: Objective: To evaluate the efficacy and safety of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) with small diameter drug-eluting beads (DEBs) in the treatment of unresectable intrahepatic cholangiocarcinoma (ICC).
Method: This article retrospectively collected clinical data of 20 patients with unresectable ICC who received small diameter DEB-TACE treatment Chinese Academy of Medical Sciences and Peking Union Medical College Cancer Hospital & Shenzhen Hospital from March 2018 to December 2023. The efficacy and safety of the treatment were analyzed by evaluating indicators such as tumor response, progression free survival (PFS), overall survival (OS), incidence of adverse events, and compared the results with other literatures on conventional diameter DEB-TACE and systemic chemotherapy.
Result: The 3-month objective response rate (ORR) and disease control rate (DCR) of 20 patients with unresectable ICC after DEB-TACE were 60.0% and 95.0%, respectively. The 6-month ORR and DCR were 30.0% and 75.0%, respectively. And the 9-month ORR and DCR were 10.0% and 45.0%, respectively. The median OS and median PFS were 16.4 months and 8.3 months, respectively. The common adverse events after DEB-TACE include bilirubin elevation,abdominal pain,nausea and vomiting, and aminotransferase elevation, all of which are grade 1 or 2, and there is no grade 3 or higher adverse events occurred.
Conclusion: DEB-TACE with small diameter DEBs is a safe and effective local treatment for unresectable ICC patients. Compared with conventional diameter DEB-TACE and systemic chemotherapy, it has similar disease control rates ,longer survival , and lower incidence of adverse events.

Key words: Drug-eluting beads transcatheter arterial chemoembolization, Small diameter drug-eluting beads, Intrahepatic cholangiocarcinoma

宣志明, 姚雪松, 宋鹏, 李书沛, 来凤勇, 冯烨霞. 小粒径载药微球经导管动脉化疗栓塞术治疗不可切除肝内胆管癌患者的疗效和安全性分析[J]. 肝癌电子杂志, 2025, 12(4): 8-13.

Xuan Zhiming, Yao Xuesong, Song Peng, Li Shupei, Lai Fengyong, Feng Yexia. Efficacy and safety analysis in the treatment of unresectable intrahepatic cholangiocarcinoma by transcatheter arterial chemoembolization with small diameter drug-eluting beads[J]. Electronic Journal of Liver Tumor, 2025, 12(4): 8-13.

参考文献

[1] MORIS D, PALTA M, KIM C, et al.Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2023, 73(2): 198-222.
[2] Siegel R L, Miller K D, Fuchs H E, et al.Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[3] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[4] BEAL E W, TUMIN D, MORIS D, et al.Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma[J]. Hepatobiliary Surg Nutr, 2018, 7(4): 270-276.
[5] SAHA S K, ZHU A X, FUCHS C S, et al.Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5): 594-599.
[6] LI H, CHEN L, ZHU G Y, et al.Interventional treatment for cholangiocarcinoma[J]. Front Oncol, 2021, 11: 671327.
[7] LIU D, WANG J, MA Z, et al.Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety[J]. Cardiovasc Intervent Radiol, 2022, 45(8): 1092-1101.
[8] SUN T, ZHANG W, CHEN L, et al.A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients[J]. J Cancer, 2022, 13(4): 1282-1288.
[9] ZHOU T Y, ZHOU G H, ZHANG Y L, et al.Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma[J]. J Cancer, 2020, 11(15): 4534-4541.
[10] MOSCONI C, SOLAINI L, VARA G, et al.Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma--a systemic review and meta-analysis[J]. Cardiovasc Intervent Radiol, 2021, 44(5): 728-738.
[11] BANALES J M, MARIN J J G, LAMARCA A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(9): 557-588.
[12] FABRITIUS M P, KHALED BEN N, KUNZ W G, et al.Image-guided local treatment for unresectable intrahepatic cholangiocarcinoma-role of interventional radiology[J]. J Clin Med, 2021, 10(23): 5574.
[13] KHAN S A, TAVOLARI S, BRANDI G. Cholangiocarcinoma: epidemiology and risk factors[J]. Liver Int, 2019, 39 Suppl 1: 19-31.
[14] BENSON A B, D'ANGELICA M I, ABBOTT D E, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5): 541-565.
[15] GUSANI N J, BALAA F K, STEEL J L, et al.Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience[J]. J Gastrointest Surg, 2008, 12(1): 129-137.
[16] HARE A E, MAKARY M S.Locoregional approaches in cholangiocarcinoma treatment[J]. Cancers (Basel), 2022, 14(23): 5853.
[17] ELVEVI A, LAFFUSA A, SCARAVAGLIO M, et al.Clinical treatment of cholangiocarcinoma: an updated comprehensive review[J]. Ann Hepatol, 2022, 27(5): 100737.
[18] HE M, JIANG N, YIN X, et al.Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis[J]. J Cancer Res Clin Oncol, 2023, 149(1): 531-540.
[19] LEE K H, LIAPI E, VENTURA V P, et al.Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver[J]. J Vasc Interv Radiol, 2008, 19(7): 1065-1069.
[20] LEE K H, LIAPI E, VOSSEN J A, et al.Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy[J]. J Vasc Interv Radiol, 2008, 19(10): 1490-1496.
[21] VALLE J, WASAN H, PALMER D H, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281.